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Variations in cell signaling pathways for different vasoconstric- A major determinant of vascular tone is the degree of
tor agonists in renal circulation of the rat. phosphorylation of myosin light chain (MLC) in vascular
Background. Major cell signaling pathways involved in ago- smooth muscle [reviewed in 1, 2]. This process can occurnist-induced vasoconstriction are recognized to be Ca2 mobili-
either by enhanced activation of MLC kinase through azation via inositol-1,4,5 triphosphate (IP3), Ca2 influx through
rise in intracellular Ca2, or by inhibition of MLC phos-l-type channels, activation of protein kinase C (PKC), and of
Rho-associated kinase (ROK). However, their contribution for phatase (Ca2 sensitization). Most of the vasoconstrictor
renal vasoconstriction induced by different agonists is not well agonists initiate these processes by binding to their spe-
characterized. cific heterotrimeric G protein–coupled receptors on vas-Methods. Increasing doses of angiotensin II (Ang II), nor-
cular smooth muscle cells. Earlier studies revealed thatepinephrine, and arginine vasopressin (AVP) were infused into
the left renal artery of anesthetized rats to reduce renal blood activated G proteins initiate three major intracellular
flow from a threshold value to about 50%. Rightward shift of signal transduction pathways [1, 2]: (1) mobilization of
the dose-response curves due to coinfusion of inhibitors served Ca2 from intracellular stores via liberation of inositol-1,
to assess contribution of different pathways: trimethoxybenzoate
4, 5 trisphosphate (IP3), (2) transmembrane influx of(TMB-8) against Ca2 mobilization, nifedipine against Ca2
Ca2, predominantly via voltage-operated l-type Ca2influx, staurosporine and Ro-318220 against PKC, and Y-27632
and HA-1077 against ROK. Effects of inhibitors were also deter- channels, and (3) activation of one or more isoforms of
mined for renal response to a single dose of U-46619, a throm- protein kinase C (PKC). Whereas the rise in intracellular
boxane A2 agonist. Composite response to U-46619 consisting Ca2 by the first two mechanisms activates the Ca2-of a fast and slow component did not permit determination of
calmodulin-dependent MLC kinase, PKC leads to Ca2dose-response curves.
sensitization by inhibiting MLC phosphatase. RecentResults. Inhibition of ROK by Y-27632 or HA-1077 had the
largest effect on renal responses to agonists. They shifted dose- studies indicate a fourth and important signal transduc-
response curves of Ang II, norepinephrine, and AVP to seven- tion pathway via activation of the monomeric small G
fold and higher values. Staurosporine, nifedipine, and TMB-8
protein Rho A and its target the Rho-associated proteinhad variable effect on agonist responses. They attenuated ef-
kinase (ROK). This has now been shown to occur viafects of Ang II and norephinephrine in an additive manner,
and each of them increased effective dose values about four- activation of heterotrimeric G proteins of G12 family [3].
fold. TMB-8 did not attenuate response to AVP and U-46619. ROK is a potent inhibitor of MLC phosphatase [4, 5]
Staurosporine and nifedipine diminished effects of AVP in a and is now considered to be the major cause of Ca2nonadditive manner, and attenuated additively the fast compo-
sensitization [reviewed in 6–8].nent of U-46619 response.
The aim of the present study was to quantify underConclusion. In contrast to other cell signaling pathways,
ROK plays a common role for all vasoconstrictor agonistsis in steady-state conditions the relative contribution of the
renal circulation. above signal transduction pathways for different vaso-
constrictor agonists in renal circulation in vivo. For this
purpose we infused increasing doses of angiotensin II
(Ang II), trimethoxybenzoate (TMB-8), norepinephrine,
arginine vasopressin (AVP), or a single dose of the stable
Key words: Rho-associated kinase, protein kinase C, L-type Ca2 chan-
thromboxane A2 (TxA2) receptor agonist U-46619 intonels, angiotensin II, norepinephrine, arginine vasopressin, U-46619,
renal blood flow. the left renal artery of anaesthetized rats and determined
the corresponding changes in renal blood flow. The con-Received for publication March 14, 2002
tribution of different signal transduction pathways wasand in revised form October 25, 2002
Accepted for publication January 28, 2002 assessed by coinfusion of inhibitors in the renal artery:
IP3 mediated sarcoplasmatic Ca2 release by TMB-8, Ca2 2003 by the International Society of Nephrology
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influx by the l-type channel blocker nifedipine, modula- confirmed by observing its maximal effect on agonist
tor effects of PKC by staurosporine and Ro-318220, and responses. The inhibitors were TMB-8 (0.2 mol/min)
Ca2 sensitization by ROK by Y-27632 and HA-1077. to block intracellular Ca2 release; nifedipine (2 nmol/
min) to block l-type Ca2 channels; staurosporine (0.3
nmol/min) or Ro-318220 (3 nmol/min) to inhibit PKCMETHODS
activation; and Y-27632 (15 nmol/min) or HA-1077 (45
Experiments were performed in female Wistar rats nmol/min) to inhibit ROK. Concentrations of inhibitors
(200 to 250 g) in accordance with local guidelines of in renal plasma, which could be estimated from renal
animal care. The animals were deprived of food the night blood flow, hematocrit, and infusion rates, were TMB-8
before the experiments but were allowed free access to (70 mol/L); nifedipine (0.7 mol/L); staurosporine (0.1
water. After anesthesia with thiobutabarbital (Inactin, mol/L); Ro-318220 (1 mol/L); Y-27632 (5 mol/L);
100 mg/kg intraperitoneally, Byk Gulden, Konstanz, and HA-1077 (15 mol/L). These values were five to ten
Germany), they were placed on a thermostat table to times above their reported inhibition content (IC)50 valuesmaintain body temperature at 36 to 37C. The trachea [10–14] except for Ro-318220 (30-fold). Preliminary ex-
was cannulated for free breathing. Cannulas were in- periments revealed that different inhibitors require dif-
serted into the left femoral vein for infusion of saline (1.5 ferent pretreatment times to develop their full effects; the
mL/hour) and into the left femoral artery for monitoring time span was longest (45 minutes) for staurosporine, inter-
mean arterial pressure (MAP). For infusion of drugs into mediate (15 minutes) for nifedipine, Ro-318220, Y-27632,
the left renal artery we used a device developed in our and HA-1077, and shortest (3 minutes) for TMB-8.
laboratory for mixing the infusate thoroughly in the lami-
nar arterial blood flow [9]. It consists of a Teflon cannula Drug preparation
connected to several lines for drug infusion and one line Ang II and AVP (Sigma Chemical Co., St. Louis, MO,
for transmitting periodical pressure oscillations. During USA) were dissolved in isotonic saline containing 10
the ejection period the oscillator produced turbulence
mol/L bovine serum albumin (BSA). Norepinehrine
in the renal artery. The Teflon cannula was first inserted
was dissolved in saline containing 0.1 mmol/L ascorbic
via the right femoral artery into the abdominal aorta
acid. Y-27632 (a generous gift from Welfide Corporation,above the left renal artery. After opening the abdomen
Osaka, Japan), Staurosporine (Sigma Chemical Co.), HA-by a subcostal left flank incision, the left renal artery
1077 (Alexis, Laeufingen, Switzerland), and TMB-8 (RBI-and adjacent aorta were freed from surrounding tissue,
Biotrend, Cologne, Germany) were dissolved in salinethen the tip of the Teflon cannula was inserted into
buffered with Tris (20 mmol/L). Stock solution of Ro-the renal artery. A continuous infusion (2 L/min) of
318220 and U-46619 were made in ethanol and dilutedheparinized saline served to keep the cannula patent. A
10- and 100-fold, respectively, with saline prior to theflow probe was placed around the left renal artery and
experiment. All solutions were stored at 20C. Nifedi-connected to a transit time flowmeter (Transonic System,
pine solution (Adalat, Bayer, Leverkusen, Germany)Inc., T 106, Ithaca, NY, USA) for measuring renal blood
contained 18 vol % ethanol and was stored at 4C. Theflow. Experiments commenced after a 30-minute stabili-
vehicles for different agents did not influence the mea-zation period.
sured parameters. Concentrations of infused drugs were
adjusted to obtain the required dose by infusing 10 l/Experimental protocols
min for the inhibitors and U-46619, and 3, 10, and 30Experiments began with intrarenal infusion of an ago-
L/min for Ang II, norepinephrine, and AVP.nist under control conditions, usually followed by a con-
trol measurement with a second agonist. Ang II, norepi-
Data evaluation and statisticsnephrine, and AVP were infused in three sequentially
Changes in renal blood blow were normalized as per-increasing doses in order to reduce renal blood flow
cent ratios of the corresponding control values and arefrom a threshold value to about 50%. Experiments with
presented as mean  SEM. To assess the shift of theU-46619 were done by employing a single dose, which
dose-response curves, a value representing the effectivereduced renal blood flow by about 20% under control
dose needed to reduce renal blood flow by 25% (ED25)conditions. In different experimental series, the measure-
was calculated for each set of measurements. This wasments were repeated after intrarenal inhibition of spe-
done by interpolation between the two log dose-responsecific cell signaling pathways, the doses of the agonists
data points above and below 25% renal blood flow reduc-(except for U-46619) being readjusted to attain a reduc-
tion [15]. The quotient of ED25 values before and aftertion in renal blood flow comparable to that during con-
intervention was used for comparison. Statistical com-trol measurements. Since all inhibitors increased basal
parisons were made by paired or unpaired t test afterrenal blood flow, submaximal doses of inhibitors were
analysis of variance. P values below 0.05 were consideredselected empirically by detecting their maximal effect
on renal blood flow and the adequacy of the dose was statistically significant.
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Fig. 1. Time course of agonist induced reductions in renal blood flow.
Angiotensin II (Ang II), 1.5 pmol/min, norepinephrine (NE), 40 pmol/
min, arginine vasopressin (AVP), 0.5 pmol/min, or U-46619, 300 pmol/
min was infused into the renal artery for 5 minutes (insets and arrows).
Fig. 2. Dose-dependent reductions in renal blood flow during intra-
renal infusions of agonists. Angiotensin II (Ang II) (A ), norepinephrine
(NE) (B ), and arginine vasopressin (AVP) (C ) under control conditions
(), during co-infusion of trimethoxybenzoate (TMB-8) () to inhibitRESULTS Ca mobilization, or of nifedipine (Nif) () to block l-type Ca channels,
or of Nif and TMB-8 together ().Hemodynamic effects of agonists
Under control conditions the MAP was 110  1
mm Hg and renal blood flow was 4.9  0.1 mL/min (N pmol/min the two components merged into a “steady
state” within the usual detection time of about 3 to 441, pooled data). Figure 1 shows examples of times
courses of reduction in renal blood flow due to intrarenal minutes. The effect of norepinephrine was the quickest
(30 seconds) followed by Ang II (1 minute) and AVPinfusions of Ang II, norepinephrine, AVP, and U-46619.
Whereas steady-state reductions in renal blood flow (	1 minute). The initial phase of U-46619 was compara-
ble to that of norepinephrine.could be obtained for Ang II, norepinephrine, and AVP
at different doses, an apparent steady state was obtained As shown in Figures 2 to 4, under control conditions
Ang II, norepinephrine, and AVP produced a dose de-for U-46619 only at the given dose. At distinctly lower
doses U-46619 caused a very slow and steady renal blood pendent reduction in renal blood flow up to about 50%.
Intrarenal infusion of the highest doses of agonists wasflow reduction without attaining a plateau within 10 min-
utes, whereas at higher doses it produced a large and associated with some spillover into the systemic circula-
tion, which could be detected by minor changes in MAP.steep transient reduction followed by a slow and steady
one, which on prolongation caused respiratory problems Norepinephrine (1 pmol/min, N  20), AVP (1 pmol/
min, N  18), and U-46619 (300 pmol/min, N  20)(pulmonary hypertension). At the present dose of 300
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Fig. 4. Dose-response curves of agonists. Angiotensin II (Ang II) (A ),Fig. 3. Dose-response curves of agonists. Angiotensin II (Ang II) (A ),
norepinephrine (NE) (B ), and arginine vasopressin (AVP) (C ) undernorepinephrine (NE) (B ), and arginine vasopressin (AVP) (C ) under
control conditions () and during coinfusion of Y-27632 () to inhibitcontrol conditions (), during coinfusion of staurosporine (Stauro) ()
activation of Rho-associated kinase.to inhibit activation of protein kinase C (PKC) alone and in combination
with nifedipine (Nif) () and trimethoxybenzoate (TMB-8) ().
TMB-8 increased renal blood flow by 31.6  2.1% and
reduced MAP by 13.9  1.1 mm Hg (N  12) vs. corre-increased MAP by 4.1  0.9 mm Hg, 7.6  0.9 mm Hg,
sponding control values.and 1.9  0.3 mm Hg, respectively, whereas Ang II (3
pmol/min, N  22) had no significant effect. The rise in
Influence of inhibitors on hemodynamicblood pressure due to higher doses of agonists used in
effects of agonistscombination with different inhibitors was marginally
higher, but did not exceed 20 mm Hg for any group. Figure 2 shows dose-response curves for Ang II, nor-
epinephrine, and AVP under control conditions and dur-
Hemodynamic effects of inhibitors ing coinfusion of TMB-8, nifedipine and TMB-8, and
nifedipine together. Figure 3 shows corresponding curvesAs shown in Figure 5, intrarenal infusion of inhibitors
using staurosporine alone and in combinations withincreased renal blood flow to a variable degree and all
nifedipine and TMB-8. The dose-response curves beforeinhibitors except TMB-8 caused small but significant re-
and after Y-27632 are depicted in Fig. 4. Table 1 givesduction in MAP. Comparable additional effects of TMB-8,
ED25 values of agonists permitting to assess rightwardnifedipine, and staurosporine were also obtained when
combined. The combination staurosporine-nifedipine- shifts of dose-response curves due to different inhibitors
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Fig. 5. Effects of different inhibitors on basal renal blood flow () and
systemic blood pressure (). TMB-8 is trimethoxybenzoate. *P  0.05
vs. control. Number of animals is given in parentheses.
including Ro-318220 and HA-1077 (dose-response curves
not shown). Table 2 shows normalized ED25 quotients
for comparing effects of inhibitors on different agonists.
The effect of Ang II on renal blood flow was attenu-
ated by inhibition of Ca2 mobilization, blockade of
l-type Ca2 channels, or inhibition of PKC activation to
a similar degree. TMB-8, nifedipine, and staurosporine
increased ED25 for Ang II about fourfold (Table 2). Com-
bination of two inhibitors increased the ED25 quotient
to about 20. Combination of all three reduced vasocon-
strictor effect of Ang II severely (Fig. 3); a reduction in
renal blood flow of 25% or more, required to determine
the ED25 value, could be obtained only in one of the six
experiments. Similar results, not permitting determina-
tion of ED25, were also obtained after inhibition of ROK
with Y-27632 (Fig. 4). The more selective PKC inhibitor
Ro-318220 also increased the ED25 quotient, but to a
lesser degree than staurosporine (P  0.05). HA-1077,
a structurally different ROK inhibitor than Y-27632, also
attenuated the effect of Ang II intensely. However, in
contrast to Y-27632, ED25 value could still be determined.
The results with norepinephrine were similar to those
with Ang II except that ED25 values could be determined
for all inhibitor combinations. ED25 values for norepi-
nephrine were increased by TMB-8, nifedipine, or stau-
rosporine (Table 1). The combinations of inhibitors also
produced additive effects (Fig. 3). However, TMB-8 in-
creased the ED25 quotient for norepinephrine more than
that for Ang II (5.5 vs. 3.5, Table 2). All combinations
with TMB-8 increased the ED25 quotient to about 30.
Y-27632 and HA-1077 increased ED25 of norepinephrine
more than any of the other inhibitors, but the corre-
sponding rise due inhibitor combinations with TMB-8
was larger. As with Ang II, also for norepinephrine the
inhibitory effect of staurosporine was greater than that
of Ro-318220.
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Table 2. Rise in ED25 due to inhibitors are given as quotient (ED25,inhibitors/ED25,control)
Nif  Stauro  Stauro  Nif
Agonist TMB-8 Nif Stauro Ro-318220 TMB-8 TMB-8 Stauro  Nif  TMB-8 Y-27632 HA-1077
Ang II 3.480.34 5.111.38 3.510.63 1.880.17 17.23.2 21.96.1 15.35.3 ND ND 19.53.1
(4.761.24) (6.752.41) (4.861.48)
NE 5.530.77a 4.040.40 3.330.55 1.710.16 27.53.5 39.96.9 8.460.89 34.29.6 11.51.7 13.01.7
(7.411.66) (12.82.0) (2.690.36) (3.940.78)
AVP 1.210.18a 2.680.47 2.220.19 1.950.16 3.010.82a 3.330.74a 2.430.21a 2.690.37 7.941.00 6.521.20a
(1.060.10a) (1.460.23a) (1.120.09a) (1.110.14)
Abbreviations are: TMB-8, trimethoxybenzoate; Nif, nifedipine; Stauro, staurosporine; ND, not determinable; Ang II, angiotensin II; NE, norepinephrine; AVP,
arginine vasopressor.
aP  0.05 vs. corresponding quotient for Ang II. Additional rise in the quotient due to the last inhibitor is given in parentheses.
remained at the last lower level after stopping U-46619
infusion. Only after stopping the infusion of TMB-8 the
flow returned to the base line value. The effect of U-46619
was eliminated by Y-27632.
DISCUSSION
In the present study, we compared roles of well-estab-
lished cell signaling pathways for different vasoconstric-
tor agonists for renal circulation in vivo. Whereas contri-
bution of Ca2 and PKC was variable, activation of ROK
was common to all agonists.
Under pathophysiologic conditions some vasocon-
strictor hormones may be involved in vital regulation of
Fig. 6. Effects of U-46619 (300 pmol/min) on renal blood flow under circulation, whereas some others, paracrine hormones,control conditions (Con) and during coinfusion of different inhibitors
could be responsible for malperfusion of a particular(N 6 for each group). Abbreviations are: TMB-8, trimethoxybenzoate;
Nif, nifedipine; Sta, staurosporine. *P  0.05 vs. control; P  0.05 organ. Therefore, understanding of their differential cell
vs. previous inhibitor. signaling pathways, which is still poor, is therapeutically
relevant. The reason for conflicting results obtained for
a given agonist should be sought in its variable transduc-
tion in different vessels (size, organ, species) as well as inDose-response curve for AVP was not affected by
the methodology of investigation (temporal resolution,TMB-8 (Fig. 2). Nifedipine and staurosporine shifted the
doses). Whereas measurements of vessel constriction incurve rightwards to a similar degree, but their effects
tissue bath are usually done on large arteries, the resultswere not additive (Table 1). With Y-27632 and HA-1077,
of organ perfusion studies depend predominantly on con-the rise in ED25 was larger than with other inhibitors.
striction of small resistance arterioles. Tissue bath studiesHowever, in contrast to Ang II and norepinephrine, in-
have shown that signal transduction during the initial,hibitory effects of staurosporine and Ro-318220 were
phasic state may differ from that during delayed, tonicsimilar for AVP.
phase of the vasoconstriction [16, 17]. Due to technicalFigure 6 depicts effects of intrarenal infusion of U-46619
reasons, however, most of the organ perfusion studies,for 3 to 4 minutes on renal blood flow under different
particularly those in vivo, measure only the transient ef-experimental conditions. The response to U-46619 was
fects of intra-arterial bolus injections on organ perfusionattenuated significantly by nifedipine and staurosporine.
[18–23]. The results gained by bolus injections could beBoth staurosporine and nifedipine attenuated the initial
particularly biased for agonists with slow kinetics, whichsteep phase of renal blood flow reduction. Surprisingly,
produce quick transient effects only at very high doses.in the presence of TMB-8 the pattern of renal blood
The approach of continuous infusion into the renalflow reduction due to U-46619 changed completely. The
artery, to attain steady state conditions, is biased byinitial phasic reduction remained practically unchanged,
uneven distribution of infused agents in laminar bloodbut instead of a following minor attenuation observed
flow in arteries. Intravenously infused substances areunder control conditions (Fig. 1), renal blood flow de-
mixed thoroughly with blood in heart ventricles, but theycreased progressively. During the observation time of 3
produce large systemic effects interfering with that onto 4 minutes renal blood flow was significantly reduced
vs. control (26.0  3.0% vs. 18.0  0.7%, Fig. 6) and the target organ. Adequate dispersion of agents in arte-
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rial blood can also be achieved via turbulence produced hand, with the bolus technique, AVP was 2.5 times less
effective than Ang II [19, 20]. It is therefore conceivableby bolus injection, but at the cost of steady state. To
overcome this problem, a device was developed in our that at high doses AVP also mobilizes intracellular Ca2
stores to produce phasic vasoconstriction. For the firstlaboratory which converts continuously infused agents
to boluses every second by using blood withdrawn from time we could demonstrate that steady-state vasocon-
striction by AVP is also dependent on PKC activation.and ejected back into the artery [9].
The effect of Ang II and norepinephrine was attenu- A reduction in renal blood flow due to a single dose
of U-46619 was attenuated both by nifedipine and staur-ated by inhibition of Ca2 mobilization, Ca2 influx, or
PKC activation in an additive manner (Fig. 3) except osporine in an apparently additive manner (Fig. 6). How-
ever, the results obtained with U-46619 should be inter-for minor quantitative differences (Table 2). Our data,
representing the response of the entire renal vascular preted only in qualitative terms because of the composite
effect of U-46619 on renal blood flow. The virtual steady-bed (renal blood flow) to agonists, are closely related to
those obtained by Feng and Arendshorst [19], Ruan and state reductions in renal blood flow obtained under con-
trol conditions were altered by nifedipine and stauro-Arendshorst [20, 21], and Salomonsson and Arendshorst
[22]. Their approach was similar but with the following sporine leading to progressive reductions indicating that
both inhibitors attenuated the initial phasic vasoconstric-three differences: they used single doses of agonists, ago-
nists and inhibitors were given as bolus injections into tion by U-46619. Due to methodologic reasons their ef-
fects on delayed tonic constriction cannot be assessedthe rat renal artery, and changes in renal blood flow
were transient. The reduction in renal blood flow due adequately. The role of Ca2 influx for the U-44069-
induced vasoconstriction (steady state) has been demon-to Ang II was attenuated by nifedipine, TMB-8 [20], and
staurosporine [21]. The effects of nifedipine and TMB-8 strated earlier in the isolated perfused normal [25] and
hydronephrotic [26] rat kidney. Though TMB-8 in-were additive [20]. The present study confirms important
roles of Ca2 influx, Ca2 mobilization, and PKC activa- creased the effect of U-46619 according to our protocol
procedure, this phenomenon does not seem to be relatedtion and extends the earlier findings [20, 21, 23] by show-
ing the additive nature of all three pathways for Ang II to inhibition of Ca2 mobilization. The pattern of renal
blood flow reduction (see Results section) rather sug-effects. The effect of bolus injection of norepinephrine
in their study was attenuated by nifedipine, and more gests that in presence of U-46619, TMB-8 was it self a
vasoconstrictor. Some complex mechanisms responsibleprominently by TMB-8. However, the effects of inhibi-
tors were not additive [22], which differs from our data. for this phenomenon remain open. However, our previ-
ous results obtained from the mesenteric circulation [15]The discrepancy may be related to a larger role of Ca2
mobilization for phasic vasoconstriction (30 seconds) indicate that steady-state vasoconstriction induced by
U-46619 is independent of Ca2 mobilization, Ca2 influxrather than for the steady-state response (3 to 4 minutes)
observed in our study. Our data extend the previous and PKC activation. In our experiments, the plasma con-
centration of U-46619 was about 150 nmol/L (renal bloodwork by showing a finite role of PKC activation for
norepinephrine-induced renal vasoconstriction. flow, 20%), in the isolated perfused kidney [25] perfu-
sate concentration was 1 mol/L (flow, 13%) and inIn contrast to Ang II and norepinephrine, renal vaso-
constriction induced by AVP was not influenced by the mesentery [15] plasma concentration was 20 nmol/L
(flow, 25%). Therefore, it is more likely that the Ca2TMB-8 at all, and effects of nifedipine and staurosporine
were not additive (Table 1). Iversen and Arendshorst influx and PKC activation are caused by high doses of
U-46619. They may not play any role during the in-[24] also found no evidence for Ca2 mobilization in
AVP-induced rise in intracellular Ca2 in smooth muscle creased TxA2 synthesis in the kidney under pathologic
conditions [27]. That U-46619–induced vasoconstrictioncells from preglomerular vessels. However, the reduction
in renal blood flow due to arterial AVP bolus injection is independent of Ca2 and PKC has also been demon-
strated for feline pulmonary circulation in vivo [28, 29].[19] was markedly attenuated by TMB-8 and to a lesser
extent by nifedipine (additive effects). In our experi- In our experiments with Ang II, norepinephrine, and
AVP we used staurosporine and Ro-318220, which arements, TMB-8, in contrast to nifedipine was ineffective.
The role of Ca2 mobilization for the effect of AVP potent inhibitors of 
,, , and ε isoforms of PKC [12, 13]
considered to be involved in agonist induced vasocon-bolus has also been demonstrated in isolated perfused
rat kidneys [19]. Also we could confirm inhibitory effect striction. However, staurosporine has also been reported
to inhibit other protein kinases, including ROK [13, 30].of TMB-8 on renal blood flow reduction induced by
AVP bolus (data not shown). This difference is probably At a concentration of 1 mol/L (vs. 0.1 mol/L in this
study) staurosporine reduced activity of purified ROK-IIattributable to the difference in methodology (bolus vs.
continuous infusion). In our experiments, AVP, a slow- by 88% [13], which was not the case with Ro-318220
[13, 31]. Inhibition of renal vascular effects of Ang IIacting vasoconstrictor (Fig. 1), was 2.5 times more effec-
tive on molar basis than Ang II (Table 1). On the other and norepinephrine but not of AVP was significantly
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more with staurosporine than with Ro-318220. How far tone. In a recent study, rabbit aortic rings denuded of
ROK or kinases other than PKC are responsible for this endothelium were treated with different agonists to pro-
difference cannot be assessed from our data. duce equivalent tension [38]. Corresponding rises in
Interestingly, differences in cell signaling pathways for measured guanosine triphosphate (GTP)-Rho/total-Rho
different agonists found in this study correlate with their ratio, an index for ROK activation, was variable. The
sites of action in the vascular bed. In the hydronephrotic highest was for U-46619, nonsignificant for Ang II, and
rat kidney, Ang II and norepinephrine (given in the intermediate for norepinephrine, histamine, and seroto-
tissue bath) have been shown to constrict predominantly nin. How far such differences have a bearing on circula-
small arterioles and interlobular artery [32]. AVP, which tion under in vivo conditions remains open.
is only moderately dependent upon the above classical
pathways, constricted larger vessels (interlobular artery
CONCLUSIONand arcuate artery) and U-46619, presumably indepen-
The present study demonstrates the central role ofdent of these pathways constricted only the arcuate ar-
ROK activation in agonist-induced vasoconstriction intery and larger conduit vessels [abstract; Parekh N et al,
the kidney. In contrast, roles of Ca2 mobilization, Ca2Pflugers Arch 439:R347, 2000].
influx, and PKC activation are variable for different ago-A central role of ROK for renal vasoconstriction in-
nists. Therefore, ROK may be regarded as therapeuticduced by all investigated agonists was evident from the
target for pathologic vasospasms induced by multiplesubstantial attenuation of agonist effects by Y-27632 and
autocrine/parcrine factors, which are resistant to otherHA-1077 (ED25-quotient7, Table 2). In a parallel study
vasodilators and inhibitors. Future investigations shouldon mesenteric circulation (unpublished data), we deter-
elucidate how far ROK inhibitors interfere with themined ED25 quotients (control/Y-27632) for Ang II, nor-
physiologic regulation of organ perfusion and functionsepinephrine, and AVP as well as for U-46619, which was
not possible in this study. Their values were similar to of nonvascular cells.
those found in the present study for Ang II, norepineph-
rine, and AVP and 9  2 for U-46619. Furthermore, ACKNOWLEDGMENTS
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